News

News Subscription

Oct 16. 2015
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Read more
Download
Oct 15. 2015
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
Read more
Download
Oct 12. 2015
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
Read more
Download
Sep 07. 2015
Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program
Read more
Download
Aug 28. 2015
Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor
Read more
Download
Aug 14. 2015
Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®
Read more
Download
Aug 12. 2015
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections
Read more
Download
Jul 30. 2015
Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections
Read more
Download
Jul 24. 2015
Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Read more
Download
Jun 25. 2015
Basilea initiates phase 1/2a oncology study with oral formulation of tumor checkpoint controller BAL101553
Read more
Download